Burning Rock Biotech (BNR) Non-Current Deffered Revenue (2019 - 2023)
Burning Rock Biotech (BNR) posted quarterly Non-Current Deffered Revenue of $39684.9 for Q4 2020, down 71.78% year-over-year from $140603.8 in Q1 2020, and up 1.76% quarter-over-quarter from $39000.0 in Q3 2020.
Burning Rock Biotech (BNR) Non-Current Deffered Revenue (2019 - 2023) Analysis & Trends
Burning Rock Biotech's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $39684.9 for Q4 2020.
- In Q4 2020, Non-Current Deffered Revenue fell 71.78% year-over-year to $39684.9; the TTM figure through Dec 2020 stood at $39684.9 (down 71.78% YoY), while the FY2020 annual figure was $40000.0, down 72.13% from the prior year.
- Non-Current Deffered Revenue for Q4 2020 stood at $39684.9, up from $39000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $140603.8 in Q4 2019, with the low at $37000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | - |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | - |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 16.07 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | - |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 32.59 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | - |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | - |
| 10 | Burning Rock Biotech | 84.09 Mn | 14.24 Mn | 11.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 59,304.92 |
| Dec 31, 2022 | 93,220.50 |
| Dec 31, 2021 | -41,135.72 |
| Dec 31, 2020 | 39,684.94 |
| Sep 30, 2020 | 39,000.00 |
| Jun 30, 2020 | 37,000.00 |
| Dec 31, 2019 | 140,603.84 |